Cargando…

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6689527/ https://www.ncbi.nlm.nih.gov/pubmed/31496768 http://dx.doi.org/10.2147/CEOR.S225177

Ejemplares similares

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer
por: Bretoni, Alberto, et al.
Publicado: (2019)

Clinical Utility of Olaparib in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review of Current Evidence and Patient Selection [Corrigendum]
Publicado: (2021)

Economic burden of the management of metastatic castrate-resistant prostate cancer in Italy: a cost of illness study [Corrigendum]
Publicado: (2018)

HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Cancer Treatments in Europe: A Patient Access Landscape Review
por: Bencina, Goran, et al.
Publicado: (2023)

Corrigendum to Clinical outcomes of volume of disease on patients receiving enzalutamide vs. abiraterone acetate plus prednisone as first-line therapy for metastatic castration resistant prostate cancer
Publicado: (2023)

Application of the HTA Core Model for complex evaluation of the effectiveness and quality of Radium-223 treatment in patients with metastatic castration resistant prostate cancer
por: Kiselova Bilekova, Beata, et al.
Publicado: (2018)

Corrigendum to “Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States”
por: Saltus, Catherine W., et al.
Publicado: (2019)

Corrigendum to: The long noncoding RNA HORAS5 mediates castration‐resistant prostate cancer survival by activating the androgen receptor transcriptional program
Publicado: (2020)

Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events
Publicado: (2015)

Corrigendum to “GUIDE: a randomised non-comparative phase II trial of biomarker-driven intermittent docetaxel versus standard-of-care docetaxel in metastatic castration-resistant prostate cancer (clinical trial protocol)”
Publicado: (2022)

Development of cabozantinib for the treatment of prostate cancer [Corrigendum]
Publicado: (2014)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2022)

Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy [Corrigendum]
Publicado: (2015)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]
Publicado: (2019)

Treatment sequencing in metastatic castrate-resistant prostate cancer
por: Sartor, Oliver, et al.
Publicado: (2014)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Mostaghel, Elahe A
Publicado: (2014)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Subcellular Organelle-Targeted Nanostructured Lipid Carriers for the Treatment of Metastatic Breast Cancer [Corrigendum]
Publicado: (2023)

Family Wellbeing and Sexual Health of Patients Receiving Treatment for Prostate Cancer [Corrigendum]
Publicado: (2023)

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
por: Sun, Wei, et al.
Publicado: (2022)

Corrigendum: IC50: an unsuitable measure for large-sized prostate cancer spheroids in drug sensitivity evaluation
Publicado: (2023)

Update on options for treatment of metastatic castration-resistant prostate cancer
por: Vishnu, Prakash, et al.
Publicado: (2010)

Editorial: Metastatic Castration Resistant Prostate Cancer: Prognosis and Treatment
por: Muniyan, Sakthivel, et al.
Publicado: (2022)

Corrigendum to “HDR Brachytherapy in the Management of High-Risk Prostate Cancer”
por: Masson, Susan, et al.
Publicado: (2016)

Corrigendum to “Fatal Systemic Vasoconstriction in a Case of Metastatic Small-Intestinal NET”
por: Stenzel, Jochen, et al.
Publicado: (2017)

Screening of hub genes and evaluation of the growth regulatory role of CD44 in metastatic prostate cancer
por: Lin, Junhao, et al.
Publicado: (2022)

Corrigendum to “Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience”
por: Karivedu, Vidhya, et al.
Publicado: (2019)

Corrigendum to Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
Publicado: (2019)

Corrigendum to: An Innovative Approach for Facial Rejuvenation and Contouring Injections in Asian Patients
por: Cui, Haiyan, et al.
Publicado: (2021)

Treatment Resistant Atopic Dermatitis: Challenges and Solutions [Corrigendum]
Publicado: (2019)

Impact of Time to Castration Resistance on Cytoreductive Radiotherapy in Metastatic Castration-Resistant Prostate Cancer
por: Mai, Lixin, et al.
Publicado: (2020)

Corrigendum to “The Current Practice of Screening, Prevention, and Treatment of Androgen-Deprivation-Therapy Induced Osteoporosis in Patients with Prostate Cancer”
por: Al-Shamsi, Humaid O., et al.
Publicado: (2017)

Corrigendum to “Harmonization of breast cancer radiotherapy treatment planning in the Netherlands” [Tech. Innov. Patient Support Radiat. Oncol. 19 (2021) 26–32]
por: Hurkmans, Coen, et al.
Publicado: (2023)

The Current Landscape of Treatment in Non-Metastatic Castration-Resistant Prostate Cancer
por: El-Amm, Joelle, et al.
Publicado: (2019)

Treatment of non-metastatic castration-resistant prostate cancer: focus on apalutamide
por: Gul, Anita, et al.
Publicado: (2019)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
por: Zobniw, Chrystia M, et al.
Publicado: (2014)

Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy
por: Mulders, Peter F., et al.
Publicado: (2015)

Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer
por: Zhang, Jingsong, et al.
Publicado: (2017)

Cost-effectiveness analysis of treatments for metastatic castration resistant prostate cancer
por: Pollard, Matthew E., et al.
Publicado: (2017)

Physician preferences for non-metastatic castration-resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_isk17u29i5hp7t9p1b5snejdho